The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets.

This report analyzes the worldwide markets for ADME-Toxicology Testing in US$ by the following Segments: Toxicology Testing (In-Vivo, In-Vitro), and ADME Testing. Market data and analytics are derived from primary and secondary research.

The report profiles 69 companies including many key and niche players such as

ACEA Biosciences, Inc. (USA)

ADMEcell, Inc. (USA)

Agilent Technologies, Inc. (USA)

Albany Molecular Research, Inc. (USA)

Beckman Coulter, Inc. (USA)

BioreclamationIVT, LLC (USA)

Cerep SA (France)

CompuDrug International, Inc. (USA)

Cyprotex PLC. (UK)

CeeTox, Inc. (USA)

Dassault Systèmes Biovia Corp. (USA)

Eurofins ADME BIOANALYSES SAS (France)

Galapagos NV (Belgium)

Molecular Discovery Ltd. (UK)

MultiCASE, Inc. (USA)

Optivia Biotechnology (USA)

PerkinElmer, Inc. (USA)

Pharmaron, Inc. (USA)

Promega Corporation (USA)

Qualyst, Inc. (USA)

Simulations Plus, Inc. (USA)

Taconic Biosciences, Inc. (USA)

Takara Bio Europe AB (Sweden)

Tecan Group Ltd. (Switzerland)

Thermo Fisher Scientific, Inc. (USA)

Key Topics Covered:

1. OUTLOOK

ADME-Tox Testing Gains Traction

A Peek into the Impact of ADME-Tox Screening on New Drug Discovery

Current and Future Analysis

US and Europe Dominate, Asia-Pacific Lends Growth Momentum

Growth Momentum Shifts Away from In Vivo Technologies; In Vitro Technologies to Lead the Charge